Moreover, the level of circulating EVs‐associated LGALS3BP positively correlated with tumour burden (Fig. 3C), thus suggesting that vesicular LGALS3BP released from GBM cancer cells may be used as potential circulating disease marker. Here, LGALS3BP is linked to neoplasm.